Type 1 Diabetes Clinical Trial
Official title:
Validation of the Gut Absorption Rate of Glucose During a Large, Slowly and Rapidly-absorbed Evening Meal in Subjects With Type 1 Diabetes
Eight adolescent and young adult subjects with type 1 diabetes, age 16−24 years, will be
recruited for this study on the basis of informed consent. Participants will be invited to
attend the Wellcome Trust Clinical Research Facility at Addenbrooke's Hospital, Cambridge,
on two occasions. On each occasion participants will arrive at the unit at 9am having
controlled their diabetes with short acting insulin for 24 hours and they will remain in the
unit until 8am the next morning. During the day, between 9am and 6pm participants will
remain fasting and their blood glucose levels will be controlled by intravenous insulin, the
dose being determined by 15−30 minute blood glucose estimations. At 1800hr on visit 1 the
subjects will be asked to ingest an evening meal enriched by a cold isotope glucose tracer
(non radioactive). The variable insulin infusion will be adjusted to allow for the meal in
order to achieve good glycaemic control after the meal until 0200hr. From then until 0800hr
in the morning the study team will again adjust the infusion rates to maintain normal
glycemia until the participants are ready to go home on their normal insulin regimen. On the
second visit the protocol will be identical until 1800hr when instead of giving the meal
variable amounts of glucose will be infused to ensure the glucose levels are identical to
those observed on visit 1. After 0200hr the study will be effectively finished but the study
team will continue to vary the insulin infusion to keep blood glucose levels normal until
the subjects can go home on their normal insulin regime at 8am.
In order to achieve sufficient information to make all the calculations needed other cold
isotope glucose tracers will be infused during the study period. These safe non radioactive
isotope tracers will enable us to assess glucose being produced by the body, its
distribution and utilization. Throughout both study periods the subjects will be monitored
very closely by a Clinical Research Fellow, assisted by a Research Nurse, in order to avoid
any risk of low blood glucose levels.
n/a
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |